Patient with locally-advanced NSCLC (Stage IIIB) treated with chemoradiation and durvalumab
**Clinical Note: Locally-Advanced Non-Small Cell Lung Cancer (NSCLC) Patient Summary**

**General Information**
- Patient Name: Michael Thompson
- Patient Date of Birth (DOB): 07/14/1957
- Patient Phone Number: (555) 623-7482
- Patient Email: michael.thompson@email.com
- Primary Care Provider: Dr. Angela Bennett, MD
- Surgeon: Dr. Lisa Wu, Thoracic Surgery
- Radiation Oncologist: Dr. Omar Farooqi, MD
- Medical Oncologist: Dr. Neil Shah, MD
- Other Providers: Nurse Coordinator: Jenny Adams, RN; Pulmonologist: Dr. Rajiv Patel, MD; Palliative Care Specialist: Dr. Emily Green, MD

**Diagnosis**
- Cancer Type/Location/Histology Subtype: NSCLC, Right Upper Lobe, Adenocarcinoma
- Diagnosis Date: 03/22/2022
- Stage: IIIB

**Treatment Completed**
- Surgery: No (deemed inoperable due to tumor location and patient comorbidities)
- Radiation Therapy: Yes
- Body Area Treated (Radiation): Right Upper Lobe of Lung
- Radiation End Date: 07/30/2022
- Systemic Therapy: Yes
- Names of Agents Used: Concurrent chemoradiation with Carboplatin and Paclitaxel
- End dates (year) of the used agents: Chemotherapy completed on 07/30/2022
- Persistent Symptoms or Side Effects at Completion of Treatment: Yes, patient reports fatigue and mild esophagitis, which are currently managed with dietary modifications and proton pump inhibitors.

**Treatment Ongoing**
- Need for Ongoing (Adjuvant) Treatment: Yes
- Additional Treatments: Patient is currently receiving adjuvant immunotherapy with durvalumab. The planned duration is for 12 months post-chemoradiation, with close monitoring for potential side effects such as pneumonitis, thyroid dysfunction, and adrenal insufficiency. Durvalumab was initiated on 09/10/2022, and the patient is tolerating the treatment well so far, with no significant immune-related adverse events reported.

**Additional Notes**
- Patient is a former smoker with a 30-pack-year history, quit 5 years ago.
- Patient has a history of well-controlled hypertension and type 2 diabetes.
- Patient lives with his spouse, who is the primary caregiver.
- The patient has completed a course of pulmonary rehabilitation and continues with prescribed exercises at home.
- The patient has expressed concerns about the financial burden of ongoing treatment, which has been addressed with the help of a hospital social worker to identify resources and support.
- The patient has an advance directive in place and has discussed end-of-life preferences with his medical oncologist and family.
- The patient is scheduled for follow-up imaging in 3 months to assess the response to adjuvant durvalumab and for ongoing monitoring of disease status.
- The patient is enrolled in a smoking cessation support group facilitated by the hospital's respiratory therapy department.
- The patient reports a good support system, including family and a local cancer support group, which has been beneficial for his mental well-being.

**Plan**
- Continue adjuvant durvalumab as tolerated, with regular follow-up appointments every 2 weeks to monitor for side effects.
- Schedule the next CT scan for disease assessment.
- Continue supportive care for symptom management.
- Review patient's medications for hypertension and diabetes in collaboration with the primary care provider to ensure optimal control.
- Provide resources for financial counseling and support as needed.
- Continue engagement with support groups and mental health resources to address the patient's emotional and psychosocial needs.